PATIENT ALERT: If you have tested positive for COVID in the last 14 days, please notify us and reschedule your appointment. Online COVID pre-screening is REQUIRED 72 hours prior to your appointment. Please CLICK HERE to complete the questionnaire.  Masks are still required in all offices.   Information regarding COVID-19.  

Clinical Research & Trials

USO 17188

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)


Disease Types: Breast Cancer Research

Eligibility Requirements:

-ER+/HER 2-  grade 3 localized invasive ductal breast adenocarcinoma T1c-T2, cN1-cN2 or T3-T4, cNo-cN2
-No: bilateral, metastatic, or multi-centric breast cancer; prior excisional biopsy of primary tumor or axillary lymph nodes or sentinel lymph node biopsy; history of non-infectious pneumonitis requiring treatment with steroids or current pneumonitis; 
immunodeficiency or condition requiring chronic steroid therapy; known active TB or Hep C or known history of HIV or Hep B

Available at: